Original Article
Primary Chemoprevention of Familial Adenomatous Polyposis with Sulindac
N Engl J Med 2002; 346:1054-1059April 4, 2002
- Abstract
Background
Familial adenomatous polyposis is caused by a germ-line mutation in the adenomatous polyposis coli gene and is characterized by the development of hundreds of colorectal adenomas and, eventually, colorectal cancer. Nonsteroidal antiinflammatory drugs can cause regression of adenomas, but whether they can prevent adenomas is unknown.
Methods
We conducted a randomized, double-blind, placebo-controlled study of 41 young subjects (age range, 8 to 25 years) who were genotypically affected with familial adenomatous polyposis but phenotypically unaffected. The subjects received either 75 or 150 mg of sulindac orally twice a day or identical-appearing placebo tablets for 48 months. The number and size of new adenomas and side effects of therapy were evaluated every four months for four years, and the levels of five major prostaglandins were serially measured in biopsy specimens of normal-appearing colorectal mucosa.
Results
After four years of treatment, the average rate of compliance exceeded 76 percent in the sulindac group, and mucosal prostaglandin levels were lower in this group than in the placebo group. During the course of the study, adenomas developed in 9 of 21 subjects (43 percent) in the sulindac group and 11 of 20 subjects in the placebo group (55 percent) (P=0.54). There were no significant differences in the mean number (P=0.69) or size (P=0.17) of polyps between the groups. Sulindac did not slow the development of adenomas, according to an evaluation involving linear longitudinal methods.
Conclusions
Standard doses of sulindac did not prevent the development of adenomas in subjects with familial adenomatous polyposis.
Media in This Article
Figure 1
Random-Effects Linear Longitudinal Analysis of the Effect of Sulindac on the Number (Panel A) and Size (Panel B) of Polyps, According to the Intention to Treat and to the Treatment Actually Received.Table 1
Demographic Characteristics of the Subjects at Base Line.Article Activity
- Article
Familial adenomatous polyposis is an autosomal dominant syndrome caused by a germ-line mutation of the adenomatous polyposis coli (APC) gene located at chromosome 5q21.1-4 The disorder is characterized by the development of hundreds of colorectal adenomas during adolescence.5 Colorectal cancer will develop in nearly all affected persons by the sixth decade of life if prophylactic colectomy is not performed.5
Regression of established adenomatous polyps in patients with familial adenomatous polyposis who received sulindac, a nonsteroidal antiinflammatory drug (NSAID), was described in case reports in 19836 and 1989.7 We and others have confirmed this observation in randomized studies of sulindac8-10 or celecoxib, a selective inhibitor of cyclooxygenase-2.11 These results led us to evaluate the ability of sulindac to prevent adenomas in subjects with the genetic abnormality of familial adenomatous polyposis who were phenotypically normal. We also measured tissue prostaglandin levels in colorectal mucosa because this is a reliable means of monitoring the local effect of NSAIDs in patients with familial adenomatous polyposis.12-14
Methods
Study Population
The study was conducted from September 1993 to July 2001. Subjects were identified and recruited from the Johns Hopkins Polyposis Registry. Written informed consent was obtained from all subjects or their parents, and assent was obtained from subjects under 18 years of age. The protocol was approved by the Johns Hopkins Joint Committee on Clinical Investigation (the institutional review board).
The genotypic and phenotypic status of all potential subjects was assessed to determine their eligibility for the trial. All potential subjects and their parents (in the case of minors) received genetic counseling before undergoing genetic testing for APC gene mutations.15 Eligible subjects were older than eight years of age and had a disease-causing mutation of the APC gene but had no endoscopically detectable colorectal adenomatous polyps and no history of colonic surgery.
The following were reasons for exclusion from the study: use of an NSAID or aspirin for more than one week in the three months preceding the study, unwillingness to discontinue taking NSAIDs, absence of the use of effective birth control in girls and young women of childbearing age, pregnancy, a white-cell count of less than 4000 per cubic millimeter, a platelet count of less than 100,000 per cubic millimeter, a blood urea nitrogen level of more than 25 mg per deciliter (8.9 mmol per liter), a serum creatinine level of more than 1.5 mg per deciliter (132.6 μmol per liter), a history of peptic ulcer disease or gastrointestinal hemorrhage, a history of cancer, active bacterial infection, use of dimethyl sulfoxide, a history of aspirin allergy, or a body weight of less than 20 kg.
Study Design
The sponsor generously supplied both sulindac and placebo but was not otherwise involved in the design or conduct of the study. Data were held by the principal investigator.
Forty-one eligible subjects entered this double-blind, placebo-controlled trial. They were randomly assigned to receive sulindac orally twice a day for four years or identical-appearing placebo tablets. The sulindac dose was calculated on the basis of body weight and adjusted according to changes in weight during the course of the study. The 11 subjects in the sulindac group who weighed 20 to 44 kg at the beginning of the study received 75 mg of sulindac orally twice a day, and the 10 who weighed more than 44 kg took 150 mg of sulindac twice a day. By the end of the study, all but three subjects were receiving the higher dose. Compliance with treatment was assessed by means of pill counts, review of subjects' diaries, and telephone calls every other week.
The development of rectosigmoid adenomatous polyps was assessed by sigmoidoscopy with an Olympus flexible video sigmoidoscope. One investigator, who did not review the records of previous examinations, made all the assessments. Evaluations were performed before treatment with sulindac or placebo was begun (month 0) and every 4 months after treatment was initiated, for a total of 48 months. At each examination, the endoscopist counted the total number of polyps in the circumference of the colorectum from 20 cm to the anal verge, and the examination was recorded on videotape. The diameter of up to five polyps just distal to 20 cm was measured in millimeters with a graduated scale passed through the biopsy channel of the sigmoidoscope. These measurements were averaged to determine the mean size of each subject's polyps.
Evaluation of Safety
Adverse effects were monitored by means of telephone interviews every two to four weeks and at each four-month visit. A complete blood count was obtained and levels of glucose, blood urea nitrogen, serum creatinine, serum electrolytes, and bilirubin were measured at each visit. Adverse events were graded in accordance with the Common Toxicity Criteria of the National Cancer Institute.16 On this scale, a score of 0 indicates no adverse effects and a score of 5 life-threatening effects.
Measurement of Prostaglandin Levels
Biopsy specimens of the rectal mucosa were obtained before the initiation of treatment (month 0), at four months, and at one, two, three, and four years with standard biopsy forceps through a flexible sigmoidoscope. Tissue specimens were obtained from the normal-appearing mucosa 20 cm from the anal verge, snap-frozen in liquid nitrogen, and stored at –70°C until further analysis. Specimens were coded to disguise the subjects' treatment assignment, and the levels of prostaglandin D2, prostaglandin E2, prostaglandin F2α, thromboxane B2, and 6-keto-prostaglandin F1α, the principal metabolite of prostacyclin, were measured by gas chromatography–mass spectrometry as described previously.12,13 The level of each prostaglandin was determined on the basis of the inclusion of known quantities of deuterated prostaglandins as internal standards. All levels of prostaglandin were adjusted for the quantity of protein in the sample.
Statistical Analysis
The primary outcome variables were the number and the size of polyps in the sulindac and placebo groups at 48 months or at the time of withdrawal from the study. Student's t-test was used to compare the two groups according to the intention-to-treat principle. The sample size was calculated to provide the study with 80 percent power to detect a difference of 1 SD in the number of polyps between groups (a two-sided alpha of 0.05).
To determine whether the treatment assignment was associated with the outcome and predictor variables, we constructed random-effects linear longitudinal models.17 These models allowed us to compare the treatment groups while adjusting for the number and the size of polyps in the same patient over time. In contrast, the t-test compares mean values at a fixed point in time. In addition, the longitudinal model assesses the simultaneous effects of treatment group, time, and noncompliance with the assigned therapy. We assumed that the longitudinal effects within subjects were random, thus essentially devising a time trend for each subject. To fit the model, the raw data had to be transformed, which made the estimated coefficient difficult to interpret clinically. Therefore, we have provided estimates of the difference between groups at the end of treatment. We fitted two series of random-effects linear longitudinal models for each of the two outcomes (the number and the size of polyps); the covariates were time (in months), an indicator of early withdrawal from the study, and the treatment group. Interactions between covariates were evaluated and retained in the model if they were significant. All analyses were performed with the use of Stata software version 6.0.18
Secondary end points were the occurrence of polyps, the histologic features of polyps (tubular, tubulovillous, or villous), and the side effects of sulindac. We used Fisher's exact test to determine whether these variables were associated with the treatment assignment.
We used Student's t-test to compare the differences in the mean percent change in prostaglandin levels from base line in the sulindac group and the placebo group and in subjects in the sulindac group in whom polyps developed and those in the sulindac group who were free of polyps. The mean percent change was calculated as the mean of prostaglandin levels at four months and one, two, three, and four years divided by the base-line prostaglandin level.
All P values were two-sided. We also used nonparametric tests in the place of t-tests and confirmed the results.
Results
Demographic Characteristics
All 41 eligible subjects had an APC gene mutation, as did their parents with familial adenomatous polyposis. Of these 41 subjects, 21 were randomly assigned to receive sulindac and 20 to receive placebo. There were no significant differences in demographic characteristics between the two groups (Table 1Table 1
Demographic Characteristics of the Subjects at Base Line.). By the end of the study, five subjects in the sulindac group had been withdrawn. Three were withdrawn because of an increasing number of polyps, and they were referred for surgical consultation. One had persistent neutropenia, and one was unable to make scheduled visits. Of the 20 subjects in the placebo group, 6 were withdrawn: 4 because of an increasing number of polyps (they were referred for surgical consultation), and 2 because they were unable to make scheduled visits.Compliance and Adverse Events
The mean (±SD) rate of compliance with treatment was 86.9±7.5 percent among patients in the sulindac group and 81.7±10.4 percent among patients in the placebo group. All subjects in the sulindac group took more than 76 percent of the scheduled doses of medication.
Treatment with sulindac for a four-year period was well tolerated. Few adverse events were reported, and 93 percent of these were minimal (grade 1) or mild (grade 2) (Table 2Table 2
Incidence and Severity of Adverse Events.). Only one subject was withdrawn from the study because of possible drug-induced persistent neutropenia. The incidence of any adverse event did not differ significantly between the sulindac group and the placebo group.Efficacy
The number of subjects in whom one or more adenomas developed during the study did not differ significantly between the groups (Table 3Table 3
Characteristics of Adenomatous Polyps at the End of Treatment.). By the end of the study, adenomas had developed in 9 of the 21 subjects in the sulindac group (43 percent) and 11 of the 20 subjects in the placebo group (55 percent) (P=0.54). The groups did not differ significantly with respect to the number of subjects with multiple adenomas, large adenomas, or advanced adenomas (tubulovillous or villous adenomas) (Table 3).Among the patients who received treatment for 40 months or more, there were no significant differences between the groups in the mean number or size of polyps (Table 4Table 4
Mean Number and Size of Adenomatous Polyps among Subjects Who Were Treated for at Least 40 Months.). According to the intention-to-treat analysis, the overall difference in the number of polyps between the sulindac group and the placebo group was 0.52 (95 percent confidence interval, –0.29 to 2.73; P=0.27). Similarly, the overall difference in the size of polyps was 0.24 (95 percent confidence interval, –0.11 to 0.75; P=0.21).Random-effects linear longitudinal analysis revealed that treatment with sulindac did not influence the number of polyps (β=0.08, P=0.23) or the size of polyps (β=0.06, P=0.13) (Figure 1Figure 1
Random-Effects Linear Longitudinal Analysis of the Effect of Sulindac on the Number (Panel A) and Size (Panel B) of Polyps, According to the Intention to Treat and to the Treatment Actually Received.).Prostaglandin Levels
There was no significant difference between the sulindac and placebo groups in the base-line levels of prostaglandins (data not shown). After treatment, levels of prostaglandins D2, E2, and F2α and thromboxane B2 were significantly lower in the sulindac group than in the control group (Table 5Table 5
Mean Percent Changes from Base Line in Prostaglandin Levels in Colorectal Mucosa.), providing additional evidence of compliance with treatment.Discussion
In this randomized, double-blind, placebo-controlled study, standard doses of sulindac did not prevent polyps in subjects who were genotypically affected with familial adenomatous polyposis but who were phenotypically unaffected initially. All subjects were carriers of APC gene mutations known to cause familial adenomatous polyposis in their parents, and there were no significant differences in base-line characteristics between the sulindac and placebo groups.
Compliance with treatment was excellent in the sulindac group. In addition, prostaglandin levels in the colorectal mucosa were significantly lower among subjects in this group than among those in the placebo group, verifying compliance with treatment. Although the amounts of sulindac we used are similar to those that have been shown to cause regression of established adenomas and reduce local prostaglandin levels, higher doses might be appropriate if another trial is planned.8-10
Evidence that sulindac has a short-lived effect on established polyps in patients with familial adenomatous polyposis has been reported. We showed that the rate of regression of adenomas was greater after six months of sulindac treatment than after nine months,8 and in some patients who had undergone ileorectal anastomosis, long-term use of sulindac resulted in the development of resistance to this medication.19,20 Moreover, colorectal cancer has developed in the rectal segment in at least three patients with familial adenomatous polyposis during maintenance therapy with sulindac.14,21,22
The lack of efficacy of primary chemoprevention could have been due to resistance to sulindac. Notably, combination treatment was more effective than sulindac alone in preventing adenomas in a murine model of familial adenomatous polyposis.23 The use of multiple drugs for both primary chemoprevention and the regression of adenomas in patients with familial adenomatous polyposis and those with hereditary nonpolyposis colorectal cancer deserves further evaluation.
In summary, our results do not provide support for the use of NSAIDs such as sulindac for the primary treatment of familial adenomatous polyposis. Prophylactic colectomy remains the treatment of choice to prevent colorectal cancer in patients with this disorder.
Supported in part by the Clayton Fund, the John G. Rangos, Sr., Charitable Foundation, and Merck and by grants (CA 53801, CA 63721, and P50 CA 62924-04) from the National Institutes of Health.
We are indebted to Ms. Linda Welch, Ms. Lilly Chua, Ms. Marianne Villani, Ms. Kathy Romans, and Dr. Mary C. Corretti for technical support.
Source Information
From the Department of Medicine (F.M.G., V.W.Y., L.M.H., A.J.K., J.D.T., D.E.G., W.H.) and the Oncology Center (F.M.G., V.W.Y., S.P., E.G.), Johns Hopkins University School of Medicine, Baltimore; Mayo Clinic, Rochester, Minn. (G.M.P.); the Department of Pathology, Academic Medical Center, Amsterdam (G.J.A.O.); and the Division of Pathology and Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston (S.R.H.).
- References
References
1
Kinzler KW ,Nilbert MC ,Su LK , et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-665
CrossRef | Web of Science | Medline2
Nishisho I ,Nakamura Y ,Miyoshi Y , et al. Mutations of chromosome 5q21 gene in FAP and colorectal cancer patients. Science 1991;253:665-669
CrossRef | Web of Science | Medline3
Groden J ,Thliveris A ,Samowitz W , et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600
CrossRef | Web of Science | Medline4
Joslyn G ,Carlson M ,Thliveris A , et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991;66:600-613
CrossRef | Web of Science5
Bussey HJR. Familial polyposis coli: family studies, histopathology, differential diagnosis, and results of treatment. Baltimore: Johns Hopkins University Press, 1975.
6
Waddell WR ,Loughry RW . Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-87
CrossRef | Web of Science | Medline7
Waddell WR ,Ganser GF ,Cerise EJ ,Loughry RW . Sulindac for polyposis of the colon. Am J Surg 1989;157:175-179
CrossRef | Web of Science | Medline8
Giardiello FM ,Hamilton SR ,Krush AJ , et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316
Full Text | Web of Science | Medline9
Nugent KP ,Farmer KCR ,Spigelman AD ,Williams CB ,Phillips RKS . Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-1619
CrossRef | Web of Science | Medline10
Labayle D ,Fischer D ,Vielh P , et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-639
Web of Science | Medline11
Steinbach G ,Lynch PM ,Phillips RKS , et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952
Full Text | Web of Science | Medline12
Yang VW ,Shields JM ,Hamilton SR , et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998;58:1750-1753
Web of Science | Medline13
Giardiello FM ,Spannhake EW ,DuBois RN , et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 1988;43:311-31614
Yang VW ,Geiman DE ,Hubbard WC , et al. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Prostaglandins Other Lipid Mediat 2000;60:83-96
CrossRef | Web of Science | Medline15
Giardiello FM ,Brensinger JD ,Petersen GM , et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997;336:823-827
Full Text | Web of Science | Medline16
Cancer Therapy Evaluation Program. Common toxicity criteria. Bethesda, Md.: National Cancer Institute, March 1998. (Accessed February 4, 2002, at http://www.fda.gov/cder/cancer/oncrefto.htm.)
17
Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. Oxford, England: Oxford University Press, 1994.
18
Stata statistical software, release 6.0. College Station, Tex.: Stata, 1999.
19
Tonelli F ,Valanzano R ,Messerini L ,Ficari F . Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol 2000;74:15-20
CrossRef | Web of Science | Medline20
Cruz-Correa MR ,Hylind LM ,Romans KE ,Bookes SV ,Giardiello F . Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2001;120:Suppl:A252-A253 abstract.
CrossRef | Web of Science21
Niv Y ,Fraser GM . Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994;107:854-857
CrossRef | Web of Science | Medline22
Thorson AG ,Lynch HT ,Smyrk TC . Rectal cancer in FAP patient after sulindac. Lancet 1994;343:180-180
CrossRef | Web of Science | Medline23
Torrance CJ ,Jackson PE ,Montgomery E , et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-1028
CrossRef | Web of Science | Medline
- Citing Articles (99)
Citing Articles
1
Shahe Boghossian, Ahmed Hawash. (2012) Chemoprevention in colorectal cancer - where we stand and what we have learned from twenty year's experience. The Surgeon 10:1, 43-52
CrossRef2
Maciej Stępnik, Magdalena Ferlińska, Anna Smok-Pieniążek, Dobrosława Gradecka-Meesters, Joanna Arkusz, Małgorzata Stańczyk. (2011) Sulindac and its metabolites: Sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines. Toxicology in Vitro 25:5, 1075-1084
CrossRef3
Brian Kim, Francis M. Giardiello. (2011) Chemoprevention in familial adenomatous polyposis. Best Practice & Research Clinical Gastroenterology 25:4-5, 607-622
CrossRef4
Leire Zubiaurre, Luis Bujanda Fernández de Pierola. (2011) Aspirina en la prevención del cáncer colorrectal. Gastroenterología y Hepatología 34:5, 337-345
CrossRef5
M. Stępnik, M. Ferlińska, A. Smok-Pieniążek, D. Gradecka-Meesters, J. Arkusz, M. Stańczyk. (2011) Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines. Medical Oncology
CrossRef6
Robert Benamouzig, Bernard Uzzan, Jacques Deyra, Antoine Martin, Stanislas Chaussade. (2011) Prevention by Aspirin of Colorectal Adenoma Recurrence: Some Advances and Latest Results of the APACC Trial. Current Colorectal Cancer Reports 7:1, 33-41
CrossRef7
Mohammed Naseer A. Khan, Yong Sup Lee. (2011) Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy. Medicinal Research Reviews 31:2, 161-201
CrossRef8
Warren Hyer. 2011. Pediatric Polyposis Syndromes. , 462-471.
CrossRef9
John Burn. (2011) Chemoprevention. Viszeralmedizin 27:4, 322-328
CrossRef10
Naim Alkhouri, James P Franciosi, Petar Mamula. (2010) Familial Adenomatous Polyposis in Children and Adolescents. Journal of Pediatric Gastroenterology and Nutrition 51:6, 727-732
CrossRef11
L. Huang, C. Zhu, Y. Sun, G. Xie, G. G. Mackenzie, G. Qiao, D. Komninou, B. Rigas. (2010) Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis 31:11, 1982-1990
CrossRef12
Su-Hyun Song, Hye-Young Min, Sang-Kook Lee. (2010) Suppression of Prostaglandin E 2 -Mediated Cell Proliferation and Signal Transduction by Resveratrol in Human Colon Cancer Cells. Biomolecules and Therapeutics 18:4, 402-410
CrossRef13
R. R. Regoes. (2010) Population genetics meets cancer genomics. Proceedings of the National Academy of Sciences 107:43, 18241-18242
CrossRef14
I. Bozic, T. Antal, H. Ohtsuki, H. Carter, D. Kim, S. Chen, R. Karchin, K. W. Kinzler, B. Vogelstein, M. A. Nowak. (2010) From the Cover: Accumulation of driver and passenger mutations during tumor progression. Proceedings of the National Academy of Sciences 107:43, 18545-18550
CrossRef15
Emily Steinhagen, Arnold J. Markowitz, José G. Guillem. (2010) How to Manage a Patient with Multiple Adenomatous Polyps. Surgical Oncology Clinics of North America 19:4, 711-723
CrossRef16
Harvey G. Moore. (2010) Colorectal Cancer: What Should Patients and Families Be Told to Lower the Risk of Colorectal Cancer?. Surgical Oncology Clinics of North America 19:4, 693-710
CrossRef17
Ignacio Alfaro, Teresa Ocaña, Antoni Castells, Carmen Cordero, Marta Ponce, Teresa Ramón Y Cajal, Montserrat Andreu, Luis Bujanda, Maite Herráiz, Antonio José Hervás Molina. (2010) Características de los pacientes con poliposis adenomatosa familiar en España. Resultados iniciales del Registro Español de Poliposis Adenomatosa Familiar. Medicina Clínica 135:3, 103-108
CrossRef18
Patrick M Lynch, Gregory D Ayers, Ernie Hawk, Ellen Richmond, Craig Eagle, Mabel Woloj, James Church, Hennie Hasson, Sherri Patterson, Elizabeth Half, Carol A Burke. (2010) The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis. The American Journal of Gastroenterology 105:6, 1437-1443
CrossRef19
D. L. H. Smith, P. Keshavan, U. Avissar, K. Ahmed, S. D. Zucker. (2010) Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor. Carcinogenesis 31:6, 1100-1109
CrossRef20
Sandra Demaria, Eli Pikarsky, Michael Karin, Lisa M. Coussens, Yen-Ching Chen, Emad M. El-Omar, Giorgio Trinchieri, Steven M. Dubinett, Jenny T. Mao, Eva Szabo, Arthur Krieg, George J. Weiner, Bernard A. Fox, George Coukos, Ena Wang, Robert T. Abraham, Michele Carbone, Michael T. Lotze. (2010) Cancer and Inflammation: Promise for Biologic Therapy. Journal of Immunotherapy 33:4, 335-351
CrossRef21
Pedro Pérez Segura, Carmen Guillén Alonso, Teresa Ramón y Cajal, Raquel Serrano Blanch, Enrique Aranda. (2010) TTD consensus document on the diagnosis and management of hereditary colorectal cancer. Clinical and Translational Oncology 12:5, 356-366
CrossRef22
John M. Carethers. (2010) Secondary Prevention of Colorectal Cancer: Is There an Optimal Follow-up for Patients with Colorectal Cancer?. Current Colorectal Cancer Reports 6:1, 24-29
CrossRef23
O. Itano, K. Yang, K. Fan, N. Kurihara, H. Shinozaki, S. Abe, B. Jin, C. Gravaghi, W. Edelmann, L. Augenlicht, L. Kopelovich, R. Kucherlapati, S. Lamprecht, M. Lipkin. (2009) Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations. Carcinogenesis 30:11, 1923-1926
CrossRef24
Chiara Porta, Paola Larghi, Monica Rimoldi, Maria Grazia Totaro, Paola Allavena, Alberto Mantovani, Antonio Sica. (2009) Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214:9-10, 761-777
CrossRef25
Wolfram Goessling, Trista E. North, Sabine Loewer, Allegra M. Lord, Sang Lee, Cristi L. Stoick-Cooper, Gilbert Weidinger, Mark Puder, George Q. Daley, Randall T. Moon, Leonard I. Zon. (2009) Genetic Interaction of PGE2 and Wnt Signaling Regulates Developmental Specification of Stem Cells and Regeneration. Cell 136:6, 1136-1147
CrossRef26
Takeo Iwama. (2009) NSAIDs and colorectal cancer prevention. Journal of Gastroenterology 44:S19, 72-76
CrossRef27
Natalia A. Ignatenko, David G. Besselsen, David E. Stringer, Karen A. Blohm-Mangone, Haiyan Cui, Eugene W. Gerner. (2008) Combination Chemoprevention of Intestinal Carcinogenesis in a Murine Model of Familial Adenomatous Polyposis. Nutrition and Cancer 60:sup1, 30-35
CrossRef28
Hang Xiao, Chung S. Yang. (2008) Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention. International Journal of Cancer 123:5, 983-990
CrossRef29
Tusar K. Desai, Donald Barkel. (2008) Syndromic Colon Cancer: Lynch Syndrome and Familial Adenomatous Polyposis. Gastroenterology Clinics of North America 37:1, 47-72
CrossRef30
Patrick M. Lynch. (2008) Chemoprevention with special reference to inherited colorectal cancer. Familial Cancer 7:1, 59-64
CrossRef31
David T. Rubin, Marcia R. Cruz-Correa, Christoph Gasche, Jeremy R. Jass, Gary R. Lichtenstein, Elizabeth A. Montgomery, Robert H. Riddell, Matthew D. Rutter, Thomas A. Ullman, Fernando S. Velayos, Steven Itzkowitz, . (2008) Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: A clinical review and update. Inflammatory Bowel Diseases 14:2, 265-274
CrossRef32
Masako Nakanishi, Antoine Ménoret, Glenn S. Belinsky, Charles Giardina, Cassandra A. Godman, Anthony T. Vella, Daniel W. Rosenberg. (2007) Utilizing endoscopic technology to reveal real-time proteomic alterations in response to chemoprevention. PROTEOMICS – CLINICAL APPLICATIONS 1:12, 1660-1666
CrossRef33
Amanda J. MacFarlane, Patrick J. Stover. (2007) Convergence of Genetic, Nutritional and Inflammatory Factors in Gastrointestinal Cancers. Nutrition Reviews 65, S157-S166
CrossRef34
Kiran Kosuri, Janusz Jankowski. (2007) Adenocarcinoma in Barrett Esophagus. Journal of Clinical Gastroenterology 41:Supplement 2, S129-S134
CrossRef35
Irfan M Hisamuddin, Vincent W Yang. (2007) Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics 8:6, 635-643
CrossRef36
Rui-Ping Pang, Jia-Guo Zhou, Zhi-Rong Zeng, Xiao-Yan Li, Wei Chen, Min-Hu Chen, Pin-Jin Hu. (2007) Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3β/NAG-1 pathway. Cancer Letters 251:2, 268-277
CrossRef37
Janindra Warusavitarne, Margaret Schnitzler. (2007) The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. International Journal of Colorectal Disease 22:7, 739-748
CrossRef38
Victoria Marsh, Alan Clarke. (2007) Intestinal homeostasis and neoplasia studied using conditional transgenesis. Expert Review of Anticancer Therapy 7:4, 519-531
CrossRef39
Y. Nancy You, Vipul T. Lakhani, Samuel A. Wells. (2007) The Role of Prophylactic Surgery in Cancer Prevention. World Journal of Surgery 31:3, 450-464
CrossRef40
Elizabeth Half, Frank A. Sinicrope. (2007) Current status of colorectal cancer chemoprevention. Current Colorectal Cancer Reports 3:1, 39-48
CrossRef41
Irfan M Hisamuddin, Mohammad A Wehbi, Vincent W Yang. (2007) Pharmacogenetics and diseases of the colon. Current Opinion in Gastroenterology 23:1, 60-66
CrossRef42
Patrick M. Lynch. (2007) Prevention of Colorectal Cancer in High-Risk Populations: The Increasing Role for Endoscopy and Chemoprevention in FAP and HNPCC. Digestion 76:1, 68-76
CrossRef43
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Chung, Daniel C., Maher, Michael M., Faquin, William C., . (2006) Case 37-2006. New England Journal of Medicine 355:22, 2349-2357
Full Text44
Eva Szabo. (2006) Selecting targets for cancer prevention: where do we go from here?. Nature Reviews Cancer 6:11, 867-874
CrossRef45
José G. Guillem, William C. Wood, Jeffrey F. Moley, Andrew Berchuck, Beth Y. Karlan, David G. Mutch, Robert F. Gagel, Jeffrey Weitzel, Monica Morrow, Barbara L. Weber, Francis Giardiello, Miguel A. Rodriguez-Bigas, James Church, Stephen Gruber, Kenneth Offit. (2006) ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Annals of Surgical Oncology 13:10, 1296-1321
CrossRef46
Paul Rozen, Finlay Macrae. (2006) Familial adenomatous polyposis: the practical applications of clinical and molecular screening. Familial Cancer 5:3, 227-235
CrossRef47
Arber, Nadir, Eagle, Craig J., Spicak, Julius, Rácz, István, Dite, Petr, Hajer, Jan, Zavoral, Miroslav, Lechuga, Maria J., Gerletti, Paola, Tang, Jie, Rosenstein, Rebecca B., Macdonald, Katie, Bhadra, Pritha, Fowler, Robert, Wittes, Janet, Zauber, Ann G., Solomon, Scott D., Levin, Bernard, . (2006) Celecoxib for the Prevention of Colorectal Adenomatous Polyps. New England Journal of Medicine 355:9, 885-895
Full Text48
Robert Gryfe. (2006) Clinical Implications of Our Advancing Knowledge of Colorectal Cancer Genetics: Inherited Syndromes, Prognosis, Prevention, Screening and Therapeutics. Surgical Clinics of North America 86:4, 787-817
CrossRef49
Jean-Baptiste Méric, Sylvie Rottey, Ken Olaussen, Jean-Charles Soria, David Khayat, Olivier Rixe, Jean-Philippe Spano. (2006) Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology 59:1, 51-64
CrossRef50
Isao Okayasu, Kiyomi Hana, Tomoko Tsuruta, Nobuyoshi Okamura, Taishi Ogawa, Wataru Tokuyama, Sabine Kajita, Tsutomu Yoshida, Tetuo Mikami. (2006) Significant increase of colonic mutated crypts correlates with age in sporadic cancer and diverticulosis cases, with higher frequency in the left- than right-side colorectum. Cancer Science 97:5, 362-367
CrossRef51
Takeo Iwama, Takayuki Akasu, Joji Utsunomiya, Tetsuichiro Muto. (2006) Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. International Journal of Clinical Oncology 11:2, 133-139
CrossRef52
Takayuki Matsumoto, Shotaro Nakamura, Motohiro Esaki, Takashi Yao, Mitsuo Iida. (2006) Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis. Journal of Gastroenterology and Hepatology 21:1, 251-257
CrossRef53
I. HILMI, KL GOH. (2006) Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs. Chinese Journal of Digestive Diseases 7:1, 1-6
CrossRef54
Yuki Young, Jonathan P. Terdiman. (2005) Endoscopic Management of Familial Colonic Neoplasia. Gastrointestinal Endoscopy Clinics of North America 15:3, 549-580
CrossRef55
Hassan Ashktorab, Fitzroy W. Dawkins, Rihab Mohamed, Daniel Larbi, Duane T. Smoot. (2005) Apoptosis Induced by Aspirin and 5-Fluorouracil in Human Colonic Adenocarcinoma Cells. Digestive Diseases and Sciences 50:6, 1025-1032
CrossRef56
Edith D Canby-Hagino, Ian M Thompson. (2005) Mechanisms of Disease: prostate cancer—a model for cancer chemoprevention in clinical practice. Nature Clinical Practice Oncology 2:5, 255-261
CrossRef57
Francis W. Nugent, Wilson C. Mertens, Stephen Graziano, Nathan Levitan, Rufus Collea, Ajeet Gajra, Janine Marshall, John McCann. (2005) Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 48:2, 267-273
CrossRef58
Francis M. Giardiello, Linda M. Hylind, Jill D. Trimbath, Stanley R. Hamilton, Katharine E. Romans, Marcia Cruz-Correa, Mary C. Corretti, G. Johan A. Offerhaus, Vincent W. Yang. (2005) Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology 128:4, 1077-1080
CrossRef59
Lisa L. Strate, Sapna Syngal. (2005) Hereditary colorectal cancer syndromes. Cancer Causes & Control 16:3, 201-213
CrossRef60
Jason R Mann, Michael G Backlund, Raymond N DuBois. (2005) Mechanisms of Disease: inflammatory mediators and cancer prevention. Nature Clinical Practice Oncology 2:4, 202-210
CrossRef61
Solomon, Scott D., McMurray, John J.V., Pfeffer, Marc A., Wittes, Janet, Fowler, Robert, Finn, Peter, Anderson, William F., Zauber, Ann, Hawk, Ernest, Bertagnolli, Monica, . (2005) Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. New England Journal of Medicine 352:11, 1071-1080
Full Text62
Sharlene Gill, Frank A. Sinicrope. (2005) Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?. Seminars in Oncology 32:1, 24-34
CrossRef63
M. Jalving, J. J. Koornstra, S. Jong, E. G. E. Vries, J. H. Kleibeuker. (2005) Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Alimentary Pharmacology and Therapeutics 21:4, 321-339
CrossRef64
Ernest T. Hawk, Asad Umar, Ellen Richmond, Jaye L. Viner. (2005) Prevention and therapy of colorectal cancer. Medical Clinics of North America 89:1, 85-110
CrossRef65
Chong-Xian Pan, Patrick Loehrer, David Seitz, Paul Helft, Beth Juliar, Rafat Ansari, William Pletcher, Jake Vinson, Liang Cheng, Christopher Sweeney. (2005) A Phase II Trial of Irinotecan, 5-Fluorouracil and Leucovorin Combined with Celecoxib and Glutamine as First-Line Therapy for Advanced Colorectal Cancer. Oncology 69:1, 63-70
CrossRef66
Martin Wagner, Guido Adler, Thomas Seufferlein. (2005) Kolorektale Karzinome: Neue Entwicklungen in der Tumorprävention und in der Diagnostik der Tumorausbreitung. Chirurgische Gastroenterologie 21:2, 109-116
CrossRef67
Peter T. Rowley. (2004) Screening for an Inherited Susceptibility to Colorectal Cancer. Genetic Testing 8:4, 421-430
CrossRef68
J.B. Tuynman, M.P. Peppelenbosch, D.J. Richel. (2004) COX-2 inhibition as a tool to treat and prevent colorectal cancer. Critical Reviews in Oncology/Hematology 52:2, 81-101
CrossRef69
Shan Zha, Vasan Yegnasubramanian, William G. Nelson, William B. Isaacs, Angelo M. De Marzo. (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Letters 215:1, 1-20
CrossRef70
Henry Lynch, Trudy Shaw, Jane Lynch, Hemant Roy. 2004. Nonsteroidal Anti-Inflammatory Drugs (NSAID) and Colorectal Cancer. .
CrossRef71
Christopher D. Lao, Dean E. Brenner. (2004) Strategies for prevention of colorectal cancer: Pharmaceutical and nutritional interventions. Current Treatment Options in Oncology 5:5, 417-426
CrossRef72
J. A. Jankowski, M. Anderson. (2004) Review article: management of oesophageal adenocarcinoma - control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Alimentary Pharmacology and Therapeutics 20:s5, 71-80
CrossRef73
Elizabeth E. Half, Robert S. Bresalier. (2004) Treatment of hereditary colorectal cancer syndromes. Current Treatment Options in Gastroenterology 7:3, 213-224
CrossRef74
Ernest T. Hawk, Asad Umar, Jaye L. Viner. (2004) Colorectal cancer chemoprevention—an overview of the science1 1This article was prepared in our capacity as employees of the U.S. Federal Government.. Gastroenterology 126:5, 1423-1447
CrossRef75
Francis M. Giardiello, Robert A. Casero, Stanley R. Hamilton, Linda M. Hylind, Jill D. Trimbath, Deborah E. Geiman, Katharine R. Judge, Walter Hubbard, G.Johan A. Offerhaus, Vincent W. Yang. (2004) Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 126:2, 425-431
CrossRef76
Tracey K. Asano, Robin S McLeod, Tracey K. Asano. 2004. Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. .
CrossRef77
Robert D Madoff, Sharon L Dykes. (2004) What's new in colon and rectal surgery. Journal of the American College of Surgeons 198:1, 91-104
CrossRef78
Elizabeth E. Half, Robert S. Bresalier. (2004) Clinical management of hereditary colorectal cancer syndromes. Current Opinion in Gastroenterology 20:1, 32-42
CrossRef79
Uri Ladabaum. (2003) Potential cost-effectiveness of colorectal cancer chemoprevention with nonsteroidal anti-inflammatory drugs. Expert Review of Pharmacoeconomics & Outcomes Research 3:6, 757-771
CrossRef80
Monica M. Bertagnolli. (2003) The potential of non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. Journal of Surgical Oncology 84:3, 113-119
CrossRef81
Cabot, Richard C.Harris, Nancy Lee, McNeely, William F., Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Chung, Daniel C., Mino, Mari, Shannon, Kristen M., . (2003) Case 34-2003. New England Journal of Medicine 349:18, 1750-1760
Full Text82
Paolo Ricchi, Sandro Pignata, Rosario Vincenzo Iaffaioli, Bruno Daniele. (2003) Cyclo-Oxygenase Inhibition in Colorectal Adenomas and Cancer. Journal of Clinical Gastroenterology 37:4, 281-287
CrossRef83
M.A Hull, S.H Gardner, G Hawcroft. (2003) Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treatment Reviews 29:4, 309-320
CrossRef84
Elham Rahme, Alan N. Barkun, Youssef Toubouti, Marc Bardou. (2003) The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125:2, 404-412
CrossRef85
Carlos R. Becerra, Eugene P. Frenkel, Raheela Ashfaq, Richard B. Gaynor. (2003) Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. International Journal of Cancer 105:6, 868-872
CrossRef86
G Huls, JJ Koornstra, JH Kleibeuker. (2003) Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. The Lancet 362:9379, 230-232
CrossRef87
Rachel H. Giles, Johan H. van Es, Hans Clevers. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1653:1, 1-24
CrossRef88
Brian A Allen, Jonathan P Terdiman. (2003) Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. Best Practice & Research Clinical Gastroenterology 17:2, 237-258
CrossRef89
Hiroshi Yasui, Masaaki Adachi, Kohzoh Imai. (2003) Combination of tumor necrosis factor-? with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice. Cancer 97:6, 1412-1420
CrossRef90
Suphat Subongkot, David Frame, William Leslie, Deborah Drajer. (2003) Selective Cyclooxygenase-2 Inhibition: A Target in Cancer Prevention and Treatment. Pharmacotherapy 23:1, 9-28
CrossRef91
Lisa A Boardman. (2002) Heritable colorectal cancer syndromes: recognition and preventive management. Gastroenterology Clinics of North America 31:4, 1107-1131
CrossRef92
Graeme P Young, Richard K Le Leu. (2002) Preventing cancer: dietary lifestyle or clinical intervention?. Asia Pacific Journal of Clinical Nutrition 11:s3, S618-S631
CrossRef93
David G Menter. (2002) Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opinion on Investigational Drugs 11:12, 1749-1764
CrossRef94
Angel Ferrández, James A. DiSario. (2002) Hereditary colorectal cancer: Screening and management. Current Treatment Options in Oncology 3:6, 459-474
CrossRef95
. (2002) Sulindac stelt teleur bij polyposis coli. Medisch-Farmaceutische Mededelingen 40:9, 277-278
CrossRef96
Levy, Rafaël, . (2002) Sulindac in Familial Adenomatous Polyposis. New England Journal of Medicine 347:8, 615-615
Full Text97
Sophie Grandjouan. (2002) Surveillance des sujets à risque très élevé de cancer colorectal (polyposes, cancer colique héréditaire sans polypose). Acta Endoscopica 32:4, 633-653
CrossRef98
Chau, Ian, Cunningham, David, . (2002) Cyclooxygenase Inhibition in Cancer — A Blind Alley or a New Therapeutic Reality?. New England Journal of Medicine 346:14, 1085-1087
Full Text99
&NA;. (2002) Sulindac for preventing adenomas in FAP?. Inpharma Weekly &NA;:1333, 13
CrossRef
- Letters
